États-Unis · Places boursières & cours · Nasdaq

Why GeneDx Holdings Stock Just Dropped 16.6%

Publié par Nasdaq · États-Unis il y a 44 min

Résumé détaillé

Key PointsGeneDx lowered its 2026 exome and genome volume growth target to at least 28% after third-quarter testing volume fell short of expectations.

Lire l'article complet sur Nasdaq Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.nasdaq.com)

Why GeneDx Holdings Stock Just Dropped 16.6%

Résumé détaillé

À lire aussi

A ‘Geologic Freak’ in Arkansas Is Big Oil’s New Lithium Bet

Four killed in Gaza after sand embankment collapses on tents

Here’s How Much Anthropic Expects to Sell Shares for When Its IPO Lands

NEAR Drops 3.5% Amid Macro Shock and Laundering News

The open AI-native stack on Kubernetes: From open models to distributed inference and agents

Stocks Stage a Broad-Based Relief Rally

Why GeneDx Holdings Stock Just Dropped 16.6%

Résumé détaillé

Partager

À lire aussi

A ‘Geologic Freak’ in Arkansas Is Big Oil’s New Lithium Bet

Four killed in Gaza after sand embankment collapses on tents

Here’s How Much Anthropic Expects to Sell Shares for When Its IPO Lands

NEAR Drops 3.5% Amid Macro Shock and Laundering News

The open AI-native stack on Kubernetes: From open models to distributed inference and agents

Stocks Stage a Broad-Based Relief Rally